Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) traded up 7.9% during trading on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. 171,529 shares traded hands during trading, a decline of 41% from the average session volume of 292,811 shares. The stock had previously closed at $19.65.

A number of other equities analysts have also recently issued reports on ELVN. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Jones Trading lowered their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, Robert W. Baird upped their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $41.20.

Insider Buying and Selling

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Friday, June 27th. The stock was sold at an average price of $20.91, for a total value of $67,957.50. Following the sale, the chief financial officer owned 23,000 shares in the company, valued at $480,930. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the sale, the chief executive officer owned 952,892 shares in the company, valued at approximately $21,135,144.56. The trade was a 1.29% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 100,111 shares of company stock valued at $1,939,549 in the last three months. Corporate insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after purchasing an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock worth $451,000 after acquiring an additional 718 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Enliven Therapeutics by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after acquiring an additional 1,285 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Enliven Therapeutics by 10.2% in the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock worth $471,000 after acquiring an additional 1,940 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Price Performance

The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -10.77 and a beta of 0.83. The firm has a fifty day simple moving average of $19.58 and a two-hundred day simple moving average of $20.35.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.